Pharmacy Practice and Positron Emission Tomography
Positron emission tomography (PET) is an imaging technique that has recently experienced growth because of its unique advantages (1). Unlike computerized axial tomography (CAT) or magnetic resonance imaging (MRI), which visualize anatomical structure, PET permits noninvasive assessment of human physiology and organ function. PET data is derived from the tissue accumulation of tracer, which is intrinsically related to the biochemical and metabolic processes that affect the radiopharmaceutical in vivo.
KeywordsPositron Emission Tomography Positron Emission Tomography Tracer Pharmacy Practice Pharmacy Student Quality Control Test
Unable to display preview. Download preview PDF.
- 1.M.E. Phelps, J.C. Mazziotta, and H.R. Schelbert, eds. “Positron Emission Tomography and Autoradiography,” Raven Press, New York (1986).Google Scholar
- 2.“Accreditation Manual, 8th Ed,” American Council on Pharmaceutical Education, Chicago, 1988.Google Scholar
- 3.“ASHP accreditation standard for residency in pharmacy practice (with an emphasis on pharmaceutical care),” Am. J. Hosp. Pharm. 49: 146 (1992).Google Scholar
- 4.“Fellowships: Policies and Guidelines,” ASHP Research and Education Foundation, Bethesda, MD (1990).Google Scholar
- 5.“FDA Public Hearing. Regulatory Approach to Positron Emission Tomography (PET) Radiopharmaceuticals: March 5, 1993,” Institute for Clinical PET, Arlington, VA (1993).Google Scholar
- 6.“FDA Center for Drug Evaluation and Research. Guide to Inspection of the Production and Control of Radiopharmaceutical Drug Products Used in Positron Emission Tomography (PET),” Food and Drug Administration, Rockville, MD (1993).Google Scholar
- 7.C.T. DeMarco. “Pharmacy and the Law,” Aspen Publishers, Rockville, MD (1984).Google Scholar
- 8.Board of Pharmaceutical Specialties. “Nuclear Pharmacy Practice Standards,” American Pharmaceutical Association, Washington, DC (1978).Google Scholar
- 9.Task Force on PET Nuclear Pharmacy. “Nuclear Pharmacy Guidelines for the Compounding of Radiopharmaceuticals for Positron Emission Tomography,” (draft), American Pharmaceutical Association, Washington, DC (1993).Google Scholar
- 10.“USP XXII / NF XVII,” The United States Pharmacopeial Convention, Rockville, MD (1990).Google Scholar